Pharmaceutical company Sarepta has announced results of Part 1 of its Phase 3 Embark gene therapy trial for Duchenne.

The trial did not meet its primary endpoint: showing a difference in a change on the North Star Ambulatory Assessment (NSAA) total score – which measures motor function in those with Duchenne.

However, improvements were observed in secondary endpoints including time to rise from the floor and the 10-metre walk test.

The study involved 125 patients with Duchenne aged 4 to 7. It was a placebo controlled, randomised trial, in which patients either received delandistrogene moxeparvovec (Elevidys) or a placebo.

Click here to read a statement from Roche, which has the commercial rights to Elevidys in the UK.

You can also read this letter to the community that has been shared by our friends at Duchenne UK.

About gene therapy

The Duchenne Research Fund was not involved in funding this particular study, however we have been proud to help propel the arena forward by funding another gene therapy, developed by Solid Biosciences. Gene therapy for Duchenne muscular dystrophy aims to deliver a microdystrophin – a functioning version of the dystrophin gene to enable the body to produce dystrophin, thereby halting the progression of the disease.

There is still plenty more work to be done to optimise this type of treatment for young people with Duchenne.

Click here to learn more about what we have funded.